Alzheimer Disease
Conditions
Brief summary
This study investigates the initial safety profile of \[18F\]P16-129 in healthy volunteers including dosimetry determination, and compares the uptake and kinetics of \[18F\]P16-129 with the FDA approved drug \[18F\]florbetapir in the brains of Alzheimer's disease patients.
Interventions
DRUG[18F]P16-129
Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
Sponsors
Five Eleven Pharma, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Part I - Brain uptake in Alzheimer's patients Inclusion Criteria 1. Signed and dated written informed consent. Capacity for consent will be determined using the Alzheimer's Association Guidelines, developed at Johns Hopkins and described in Alzheimer's Association Consensus Recommendation: Research consent for cognitively impaired adults: Guidelines for Institutional Review Boards and Investigators (Alzheimer's Association 2004). 2. Have a study partner able to accompany the subject to all visits and answer questions about the subject. 3. Male or female, \> 50 years of age 4. Have a diagnosis of probable AD, according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria 5. The patient has a Mini Mental State Examination (MMSE) score at screening of at least 15 and no greater than 26. 6. Female patients must have had her last natural menstruation at least ≥24 months prior to the Screening Visit or have been surgically sterilized prior to the Screening Visit. Male patients must use two methods of contraception in combination if his female partner is of childbearing potential; OR have been surgically sterilized prior to the Screening Visit. 7. In the opinion of the investigator based on medical history and physical examination, can safely tolerate tracer administration and the scanning procedures.
Exclusion criteria
1. History or presence of a significant neurological diagnosis (other than AD) that may influence the outcome or analysis of the scan results; examples include but are not limited to stroke, traumatic brain injury, space occupying lesions, major head trauma, and Parkinson's disease. 2. History or presence of any clinically relevant hematological, hepatic, respiratory, cardiovascular, renal, metabolic, endocrine, or CNS disease or other medical conditions that are not well controlled, may put the subject at risk, could interfere with the objectives of the study, or make the subject unsuitable for participation in the study for any other reason in the opinion of the principal investigator. 3. The patient has a history of seizures, with the exception of childhood febrile seizures. 4. History of positive HIV, hepatitis B surface antigen (HBsAg), or hepatitis C virus / antibodies (anti-HCV) 5. Clinically relevant pathological findings in physical examination, ECG, vital signs, or laboratory values at the screening assessment that could interfere with the objectives of the study. 6. Have current clinically significant cardiovascular disease. The patient has, at the Screening Visit: an abnormal ECG that is, in the investigator's opinion, clinically significant, a QTcF \> 470 ms. 7. Has had or is planning to have exposure to ionizing radiation that in combination with the study-related tracer administrations and scanning procedures would result in a cumulative exposure that exceeds recommended exposure limits. 8. Contraindications of MRI. Incidental findings on MRI scans that are pathognomonic for an active disease or pathological process which requires medical intervention will be exclusionary. 9. History of, or suffers from, claustrophobia or feels that he or she will be unable to lie still on their back in the MRI or PET scanner. 10. Patients who have received an investigational medication within the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication. Part II - Dosimetry in Healthy Volunteers Inclusion Criteria 1. Healthy non-smoking males and females, as determined by medical history, physical examination, vital signs, clinical laboratory tests, and an electrocardiogram. 1.1 Male subjects and their child bearing potential partners must be willing to use a reliable method of birth control for the duration of the study. 1.2 Female subjects who are of childbearing potential must agree to use an adequate method of contraception for the duration of the study. 2. Between 18-45 years old, inclusive. 3. BMI between 18-30 kg/m2 inclusive. 4. Have clinical laboratory test results within the reference ranges for the population or results within acceptable deviations that are not considered by the investigator to be clinically significant. 5. All subjects and their partners of childbearing potential must commit to use two methods of contraception, one of which must be a barrier method, from the time of screening and throughout the study and until follow-up. 6. Less than 195 cm (6 feet and 5 inches) tall in order to accommodate the whole body scanning. 7. Have sufficient venous access.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Regional brain uptake of [18F]P16-129 and [18F]florbetapir | 30 - 90 minutes post injection | Quantitative estimates of amyloid distribution in brain - SUV and SUVR |
| Cumulative organ [18F]P16-129 activity for estimates of radiation absorbed dose and effective dose | 0 - 240 min post injection | dosimetry |
Countries
United States
Outcome results
None listed